PK-Directed Intravenous Busulfan in Combination with High-Dose Melphalan and Bortezomib As Conditioning Regimen for Patients with Multiple Myeloma

被引：1
作者：
Barta, Stefan Klaus [1 ]
Mazumder, Amitabha [2 ]
Carter, Jason [1 ]
Almanzar, Lawrence [1 ]
Elkind, Richard [1 ]
Battini, Ramakrishna [1 ]
Derman, Olga [1 ]
Kornblum, Noah [1 ]
Xue, Xionan [3 ]
Verma, Amit [1 ]
Braunschweig, Ira [1 ]
机构：
[1] Montefiore Med Ctr, Bronx, NY 10467 USA
[2] NYU Canc Ctr, New York, NY USA
[3] Albert Einstein Canc Ctr, Bronx, NY USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2014年 / 20卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2013.12.146
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
126
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [21] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    Dunia, D. M.
    Dolores, M.
    Dolores, S.
    Nuria, G.
    Miguel, D.
    Jaime, A.
    Helga, G.
    Alejandro, V.
    Sonia, H.
    Blanca, P.
    HAEMATOLOGICA, 2016, 101 : 862 - 862
  • [22] Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up
    Nishiyama, Risa
    Kagoo, Toshiya
    Ueno, Hironori
    Yokoyama, Akihiro
    IN VIVO, 2025, 39 (01): : 340 - 345
  • [23] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    de Miguel, D.
    Morales, D.
    San Roman, I.
    Golbano, N.
    Diaz, M.
    Arbeteta, J.
    Herrero, S.
    Subira, D.
    PInedo, B.
    HAEMATOLOGICA, 2012, 97 : 622 - 622
  • [24] Single daily dose of intravenous busulfan and melphalan as conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation
    de la Rubia, J.
    Lahuerta, J.
    Gonzalez, J.
    Solano, C.
    Rivas, P.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S323 - S323
  • [25] The effectiveness of the conditioning regimen high dose melphalan with bortezomib with autologous transplantation of hematopoietic stem cells in patients with multiple myeloma
    Khorobrykh, Marina
    Zorina, Natalia
    Minaeva, Natalia
    Sherstnev, Philipp
    Paramonov, Igor
    BONE MARROW TRANSPLANTATION, 2018, 53 : 293 - 294
  • [26] Busulfan / Melphalan / Bortezomib (Bu-Mel-Vet) Vs. High Dose Melphalan As Conditioning Regimen For Autologous Hematopoietic Cell Transplantation In Multiple Myeloma (MM)
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Zhong, Xiaobo
    Sterrenberg, Danielle
    Vesole, David H.
    BLOOD, 2013, 122 (21)
  • [27] High-Dose Melphalan Versus Busulfan, Cyclophosphamide As Conditioning Regimens for Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
    Styler, Michael
    Crilley, Pamela Ann
    Jain, Maneesh
    Ward, Kristine
    Topolsky, David
    Cho, David
    Kim, Marc
    BLOOD, 2015, 126 (23)
  • [28] Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)
    Kim, Mihee
    Lee, Je-Jung
    Min, Chang-Ki
    Lee, Ji Yun
    Jo, Jae-Cheol
    Yoon, Sung-Soo
    Lim, Sung-Nam
    Do, Young Rok
    Kim, Kihyun
    Lee, Jae Hoon
    Yoo, Kwai Han
    Bae, Sung Hwa
    Yi, Jun Ho
    Jung, Jongheon
    Eom, Hyeon-Seok
    Jung, Sung-Hoon
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2233 - 2240
  • [29] High-dose melphalan in patients with multiple myeloma
    Moreau, P
    Le Bonniec, M
    Harousseau, JL
    BULLETIN DU CANCER, 1999, 86 (03) : 283 - 288
  • [30] Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)
    Mihee Kim
    Je-Jung Lee
    Chang-Ki Min
    Ji Yun Lee
    Jae-Cheol Jo
    Sung-Soo Yoon
    Sung-Nam Lim
    Young Rok Do
    Kihyun Kim
    Jae Hoon Lee
    Kwai Han Yoo
    Sung Hwa Bae
    Jun Ho Yi
    Jongheon Jung
    Hyeon-Seok Eom
    Sung-Hoon Jung
    Annals of Hematology, 2023, 102 : 2233 - 2240
12345